Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2
• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity.
Autor*in: |
Malipiero, Giacomo [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Schlagwörter: |
---|
Umfang: |
7 |
---|
Übergeordnetes Werk: |
Enthalten in: Li-CO - Zhang, Peng-Fang ELSEVIER, 2022, international journal of clinical chemistry and applied molecular biology, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:524 ; year:2022 ; day:1 ; month:01 ; pages:11-17 ; extent:7 |
Links: |
---|
DOI / URN: |
10.1016/j.cca.2021.11.023 |
---|
Katalog-ID: |
ELV056254210 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV056254210 | ||
003 | DE-627 | ||
005 | 20230624230710.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220105s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.cca.2021.11.023 |2 doi | |
028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica |
035 | |a (DE-627)ELV056254210 | ||
035 | |a (ELSEVIER)S0009-8981(21)00413-7 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 660 |q VZ |
082 | 0 | 4 | |a 660 |q VZ |
084 | |a 58.10 |2 bkl | ||
100 | 1 | |a Malipiero, Giacomo |e verfasserin |4 aut | |
245 | 1 | 0 | |a Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
264 | 1 | |c 2022 | |
300 | |a 7 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. | ||
650 | 7 | |a COVID-19 |2 Elsevier | |
650 | 7 | |a SARS-CoV-2 |2 Elsevier | |
650 | 7 | |a BNT162b2 |2 Elsevier | |
650 | 7 | |a Immunogenicity |2 Elsevier | |
650 | 7 | |a Anti-S-RBD |2 Elsevier | |
650 | 7 | |a Neutralizing antibody |2 Elsevier | |
700 | 1 | |a D'Agaro, Pierlanfranco |4 oth | |
700 | 1 | |a Segat, Ludovica |4 oth | |
700 | 1 | |a Moratto, Anna |4 oth | |
700 | 1 | |a Villalta, Danilo |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Zhang, Peng-Fang ELSEVIER |t Li-CO |d 2022 |d international journal of clinical chemistry and applied molecular biology |g Amsterdam [u.a.] |w (DE-627)ELV008356149 |
773 | 1 | 8 | |g volume:524 |g year:2022 |g day:1 |g month:01 |g pages:11-17 |g extent:7 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.cca.2021.11.023 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 58.10 |j Verfahrenstechnik: Allgemeines |q VZ |
951 | |a AR | ||
952 | |d 524 |j 2022 |b 1 |c 0101 |h 11-17 |g 7 |
author_variant |
g m gm |
---|---|
matchkey_str |
malipierogiacomodagaropierlanfrancosegat:2022----:ogemeaoatrdgttratrn122acntointirrdyosfetai |
hierarchy_sort_str |
2022 |
bklnumber |
58.10 |
publishDate |
2022 |
allfields |
10.1016/j.cca.2021.11.023 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica (DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 DE-627 ger DE-627 rakwb eng 660 VZ 660 VZ 58.10 bkl Malipiero, Giacomo verfasserin aut Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 2022 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier D'Agaro, Pierlanfranco oth Segat, Ludovica oth Moratto, Anna oth Villalta, Danilo oth Enthalten in Elsevier Science Zhang, Peng-Fang ELSEVIER Li-CO 2022 international journal of clinical chemistry and applied molecular biology Amsterdam [u.a.] (DE-627)ELV008356149 volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 https://doi.org/10.1016/j.cca.2021.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.10 Verfahrenstechnik: Allgemeines VZ AR 524 2022 1 0101 11-17 7 |
spelling |
10.1016/j.cca.2021.11.023 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica (DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 DE-627 ger DE-627 rakwb eng 660 VZ 660 VZ 58.10 bkl Malipiero, Giacomo verfasserin aut Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 2022 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier D'Agaro, Pierlanfranco oth Segat, Ludovica oth Moratto, Anna oth Villalta, Danilo oth Enthalten in Elsevier Science Zhang, Peng-Fang ELSEVIER Li-CO 2022 international journal of clinical chemistry and applied molecular biology Amsterdam [u.a.] (DE-627)ELV008356149 volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 https://doi.org/10.1016/j.cca.2021.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.10 Verfahrenstechnik: Allgemeines VZ AR 524 2022 1 0101 11-17 7 |
allfields_unstemmed |
10.1016/j.cca.2021.11.023 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica (DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 DE-627 ger DE-627 rakwb eng 660 VZ 660 VZ 58.10 bkl Malipiero, Giacomo verfasserin aut Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 2022 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier D'Agaro, Pierlanfranco oth Segat, Ludovica oth Moratto, Anna oth Villalta, Danilo oth Enthalten in Elsevier Science Zhang, Peng-Fang ELSEVIER Li-CO 2022 international journal of clinical chemistry and applied molecular biology Amsterdam [u.a.] (DE-627)ELV008356149 volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 https://doi.org/10.1016/j.cca.2021.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.10 Verfahrenstechnik: Allgemeines VZ AR 524 2022 1 0101 11-17 7 |
allfieldsGer |
10.1016/j.cca.2021.11.023 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica (DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 DE-627 ger DE-627 rakwb eng 660 VZ 660 VZ 58.10 bkl Malipiero, Giacomo verfasserin aut Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 2022 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier D'Agaro, Pierlanfranco oth Segat, Ludovica oth Moratto, Anna oth Villalta, Danilo oth Enthalten in Elsevier Science Zhang, Peng-Fang ELSEVIER Li-CO 2022 international journal of clinical chemistry and applied molecular biology Amsterdam [u.a.] (DE-627)ELV008356149 volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 https://doi.org/10.1016/j.cca.2021.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.10 Verfahrenstechnik: Allgemeines VZ AR 524 2022 1 0101 11-17 7 |
allfieldsSound |
10.1016/j.cca.2021.11.023 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica (DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 DE-627 ger DE-627 rakwb eng 660 VZ 660 VZ 58.10 bkl Malipiero, Giacomo verfasserin aut Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 2022 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier D'Agaro, Pierlanfranco oth Segat, Ludovica oth Moratto, Anna oth Villalta, Danilo oth Enthalten in Elsevier Science Zhang, Peng-Fang ELSEVIER Li-CO 2022 international journal of clinical chemistry and applied molecular biology Amsterdam [u.a.] (DE-627)ELV008356149 volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 https://doi.org/10.1016/j.cca.2021.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.10 Verfahrenstechnik: Allgemeines VZ AR 524 2022 1 0101 11-17 7 |
language |
English |
source |
Enthalten in Li-CO Amsterdam [u.a.] volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 |
sourceStr |
Enthalten in Li-CO Amsterdam [u.a.] volume:524 year:2022 day:1 month:01 pages:11-17 extent:7 |
format_phy_str_mv |
Article |
bklname |
Verfahrenstechnik: Allgemeines |
institution |
findex.gbv.de |
topic_facet |
COVID-19 SARS-CoV-2 BNT162b2 Immunogenicity Anti-S-RBD Neutralizing antibody |
dewey-raw |
660 |
isfreeaccess_bool |
false |
container_title |
Li-CO |
authorswithroles_txt_mv |
Malipiero, Giacomo @@aut@@ D'Agaro, Pierlanfranco @@oth@@ Segat, Ludovica @@oth@@ Moratto, Anna @@oth@@ Villalta, Danilo @@oth@@ |
publishDateDaySort_date |
2022-01-01T00:00:00Z |
hierarchy_top_id |
ELV008356149 |
dewey-sort |
3660 |
id |
ELV056254210 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056254210</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624230710.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cca.2021.11.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056254210</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0009-8981(21)00413-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Malipiero, Giacomo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COVID-19</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SARS-CoV-2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BNT162b2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunogenicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-S-RBD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neutralizing antibody</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">D'Agaro, Pierlanfranco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Segat, Ludovica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moratto, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Villalta, Danilo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Zhang, Peng-Fang ELSEVIER</subfield><subfield code="t">Li-CO</subfield><subfield code="d">2022</subfield><subfield code="d">international journal of clinical chemistry and applied molecular biology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV008356149</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:524</subfield><subfield code="g">year:2022</subfield><subfield code="g">day:1</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:11-17</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cca.2021.11.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.10</subfield><subfield code="j">Verfahrenstechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">524</subfield><subfield code="j">2022</subfield><subfield code="b">1</subfield><subfield code="c">0101</subfield><subfield code="h">11-17</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
author |
Malipiero, Giacomo |
spellingShingle |
Malipiero, Giacomo ddc 660 bkl 58.10 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
authorStr |
Malipiero, Giacomo |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008356149 |
format |
electronic Article |
dewey-ones |
660 - Chemical engineering |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
660 VZ 58.10 bkl Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody Elsevier |
topic |
ddc 660 bkl 58.10 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody |
topic_unstemmed |
ddc 660 bkl 58.10 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody |
topic_browse |
ddc 660 bkl 58.10 Elsevier COVID-19 Elsevier SARS-CoV-2 Elsevier BNT162b2 Elsevier Immunogenicity Elsevier Anti-S-RBD Elsevier Neutralizing antibody |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
p d pd l s ls a m am d v dv |
hierarchy_parent_title |
Li-CO |
hierarchy_parent_id |
ELV008356149 |
dewey-tens |
660 - Chemical engineering |
hierarchy_top_title |
Li-CO |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV008356149 |
title |
Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
ctrlnum |
(DE-627)ELV056254210 (ELSEVIER)S0009-8981(21)00413-7 |
title_full |
Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
author_sort |
Malipiero, Giacomo |
journal |
Li-CO |
journalStr |
Li-CO |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
zzz |
container_start_page |
11 |
author_browse |
Malipiero, Giacomo |
container_volume |
524 |
physical |
7 |
class |
660 VZ 58.10 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Malipiero, Giacomo |
doi_str_mv |
10.1016/j.cca.2021.11.023 |
dewey-full |
660 |
title_sort |
long-term decay of anti-rbd igg titers after bnt162b2 vaccination is not mirrored by loss of neutralizing bioactivity against sars-cov-2 |
title_auth |
Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
abstract |
• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. |
abstractGer |
• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. |
abstract_unstemmed |
• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
title_short |
Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 |
url |
https://doi.org/10.1016/j.cca.2021.11.023 |
remote_bool |
true |
author2 |
D'Agaro, Pierlanfranco Segat, Ludovica Moratto, Anna Villalta, Danilo |
author2Str |
D'Agaro, Pierlanfranco Segat, Ludovica Moratto, Anna Villalta, Danilo |
ppnlink |
ELV008356149 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth |
doi_str |
10.1016/j.cca.2021.11.023 |
up_date |
2024-07-06T19:52:10.260Z |
_version_ |
1803860605937909760 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056254210</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624230710.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cca.2021.11.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001655.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056254210</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0009-8981(21)00413-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Malipiero, Giacomo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Anti-SARS-CoV-2 BNT162b2 vaccine is highly immunogenic in COVID-19 naïve HCWs. • Anti-RBD antibodies are highly correlated to neutralizing bioactivity. • Quantitative anti-RBD IgG should not be used alone to define neutralizing antibody activity.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">COVID-19</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SARS-CoV-2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BNT162b2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunogenicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-S-RBD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neutralizing antibody</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">D'Agaro, Pierlanfranco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Segat, Ludovica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moratto, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Villalta, Danilo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Zhang, Peng-Fang ELSEVIER</subfield><subfield code="t">Li-CO</subfield><subfield code="d">2022</subfield><subfield code="d">international journal of clinical chemistry and applied molecular biology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV008356149</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:524</subfield><subfield code="g">year:2022</subfield><subfield code="g">day:1</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:11-17</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cca.2021.11.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.10</subfield><subfield code="j">Verfahrenstechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">524</subfield><subfield code="j">2022</subfield><subfield code="b">1</subfield><subfield code="c">0101</subfield><subfield code="h">11-17</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
score |
7.4000454 |